8-K filing — SCYNEXIS INC (SCYX)
Filed: 2026-09-28 AccNo: 0001178253-26-000037 Size: 210 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
SCYNEXIS Completes Phase 1 Study Of SCY-770, Selective And Direct AMP-Activated Protein Kinase Activator
• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
SCYNEXIS Announces $214M BARDA Contract For Antifungal SCY-247, With About $18.5M In Initial Funding
SCYNEXIS Appoints Sanjay Subramanian As CFO, Effective September 9
Mr. Subramanian brings more than 20 years of finance, capital markets, business development and operational leadership experience across the biotechnology, pharmaceutical and healthcare sectors. Most recently, he served